[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612911":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":30,"locations":36,"responsibleParty":49,"collaborators":53,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":59,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":26,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":79,"overallStatus":38,"whyStopped":26,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Instituto Dante Pazzanese de Cardiologia","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Simplified Fixed-Dose Triple Combination","EXPERIMENTAL","Randomized participants in this group discontinue their previous antihypertensive medications and replace them with the single-pill triple fixed-dose combination. Treatment adjustments may be made if required according to office blood pressure measurements.",[13],"Drug: Triple Fixed-Dose Combination (Perindoprile\u002FIndapamide\u002FAmlodipine)",{"label":15,"type":16,"description":17,"interventionNames":18},"Usual Care Antihypertensive Regimen","ACTIVE_COMPARATOR","Participants continue their usual antihypertensive treatment regimen, consisting of up to five drug classes administered as separate tablets, for 12 weeks, with medication adjustments performed as needed according to office blood pressure measurements.",[19],"Drug: Usual Care Antihypertensive Regimen",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Triple Fixed-Dose Combination (Perindoprile\u002FIndapamide\u002FAmlodipine)","Participants receive a fixed-dose tablet containing perindopril 10 mg, indapamide 2.5 mg, and amlodipine 10 mg administered once daily for 12 weeks. Randomized participants in this group discontinue their previous antihypertensive medications and replace them with the single-pill triple fixed-dose combination. Treatment adjustments may be made if required according to office blood pressure measurements",[9],null,{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"Participants continue their usual antihypertensive therapy, consisting of up to five drug classes administered as separate tablets. Medication types and doses are adjusted by the investigator as needed to achieve office blood pressure control, following standard clinical practice. Treatment modifications are permitted throughout the 12-week study period according to clinical judgment and blood pressure response.",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":26,"email":35},"Antonio G Laurinavicius, MD, PhD","CONTACT","5511996695389","antonio.laurinavicius@gmail.com",[37],{"facility":5,"status":38,"city":39,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":26},"RECRUITING","São Paulo","04012909","Brazil","BR",{"type":44,"coordinates":45},"Point",[46,47],-46.63611,-23.5475,{"lat":47,"lon":46},{"type":50,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Fabrizio Urbinati Maroja","MD, MSc",[54],{"name":55,"class":56},"Servier","INDUSTRY","100612911","rapid-management-of-resistant-hypertension-in-the-public-health-system-fast-control-100612911",false,"NCT07259733","Rapid Management of Resistant Hypertension in the Public Health System (Fast Control)","Strategy for Rapid Control of Apparent Resistant Arterial Hypertension in the Public Health System (FAST Control)","FastControl","Inclusion Criteria: Age between 18 and 75 years;\n\nTreatment with 3 to 5 classes of antihypertensive drugs, including a maximum dose of an ACE inhibitor or ARB, a thiazide or thiazide-like diuretic, and a calcium channel blocker (CCB);\n\nRecent 24-hour ambulatory blood pressure monitoring (ABPM) (\\\u003C1 month) showing values above target (24-hour BP ≥130\u002F80 mmHg);\n\nOffice blood pressure ≥140\u002F90 mmHg;\n\nPoor adherence to treatment, defined as a score ≥1 point on the Morisky Medication Adherence Scale (MMAS-4).\n\n\\-\n\nExclusion Criteria:Secondary hypertension (including hyperaldosteronism, pheochromocytoma, or renovascular hypertension);\n\nHistory of intolerance or adverse reactions to study medications, such as ACE inhibitors (cough or angioedema), thiazide or thiazide-like diuretics (electrolyte disturbances), or calcium channel blockers (significant ankle edema or headache);\n\nIndispensable use of beta-blockers or mineralocorticoid receptor antagonists;\n\nOffice blood pressure ≥ 220 × 120 mmHg;\n\nReduced left ventricular ejection fraction (LVEF \\\u003C 55%);\n\nSevere renal impairment (creatinine clearance \\\u003C 30 mL\u002Fmin or eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²);\n\nAtrial fibrillation or atrial flutter;\n\nUse of oral anticoagulants;\n\nSignificant valvular heart disease;\n\nBody mass index (BMI) ≥ 40 kg\u002Fm²;\n\nPregnant or breastfeeding women;\n\nSevere psychiatric disorders;\n\nActive malignancy with life expectancy \\\u003C 2 years;\n\n\\-","ALL","18 Years","75 Years",{"count":69,"type":70},142,"ESTIMATED","INTERVENTIONAL",[73],"NA","This is a single-center, open-label, randomized clinical trial conducted at the Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil. The study evaluates a simplified treatment strategy for patients with apparent resistant hypertension, comparing fixed triple combination therapy (perindopril, indapamide, and amlodipine) with usual care using multiple separate antihypertensive drugs. The primary objective is to compare 24-hour blood pressure control as measured by ABPM at 12 weeks between the two treatment strategies. Enrollment began on July 15, 2023, and this study was registered retrospectively.",[76,77,78],"Apparent Resistant Hypertension","Hypertension","High Blood Pressure",[80],"Apparent resistant hypertension; Fixed-dose combination; Triple combination therapy; Perindoprile; Indapamide; Amlodipine; Clinical Trial; Brazil","2025-11-21",{"date":83,"type":84},"2025-12-02","ACTUAL",{"date":86,"type":84},"2023-07-15",{"date":88,"type":70},"2026-12-31",{"name":5,"class":6},1]